within Pharmacolibrary.Drugs.ATC.L;

model L04AE03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.841,
    Cl             = 5.183333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2.0 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.124,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005666666666666667,
    Tlag           = 10.020000000000001,            
    Vdp             = 1.55,
    k12             = 11.4,
    k21             = 11.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AE03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Siponimod is a selective sphingosine 1-phosphate receptor modulator used primarily for the treatment of relapsing forms of multiple sclerosis (MS), including secondary progressive MS with active disease. It is currently approved and available for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Biswal, S, et al., &amp; Legangneux, E (2014). Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects. <i>International journal of clinical pharmacology and therapeutics</i> 52(11) 996–1004. DOI:<a href=&quot;https://doi.org/10.5414/CP202142&quot;>10.5414/CP202142</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25161159/&quot;>https://pubmed.ncbi.nlm.nih.gov/25161159</a></p></li><li><p>Shakeri-Nejad, K, et al., &amp; Legangneux, E (2020). Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects. <i>Clinical therapeutics</i> 42(1) 175–195. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2019.11.014&quot;>10.1016/j.clinthera.2019.11.014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31926605/&quot;>https://pubmed.ncbi.nlm.nih.gov/31926605</a></p></li><li><p> (2020). Ozanimod (Zeposia) for multiple sclerosis. <i>The Medical letter on drugs and therapeutics</i> 62(1605) 132–134. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32970043/&quot;>https://pubmed.ncbi.nlm.nih.gov/32970043</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AE03;
